Earnings Surprise Are On Cards For CymaBay Therapeutics Inc. ($CBAY)?

84

CymaBay Therapeutics Inc. (NASDAQ:CBAY) is reporting second quarter financial results on Monday 10th August 2020, after market close.

According to analysts surveyed by Thomson Reuters, CBAY is expected to report 2Q20 loss of $ 0.24 per share.

For the full year, analysts anticipate loss of $ 0.91 per share bottom line.

Previous Quarter Performance

CymaBay Therapeutics Inc. revealed loss for the first quarter of $ 0.19 per share, from the revenue of . The consensus estimates are loss of $ 0.30 per share The bottom line results beat street analysts by $ 0.11 or 36.67 percent, at the same time, top line results analysts by $ 3.33 million or .

wpDataChart with provided ID not found! wpDataTable with provided ID not found!
Stock Performance

According to the previous trading day, closing price of CBAY was $ 6.26, representing a 417.36 % increase from the 52 week low of $ 1.21 and a 4.57 % decrease over the 52 week high of $ 6.56.

The company has a market capital of $ 394.70 million and is part of the Healthcare sector and Biotechnology industry.

[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CBAY” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]

Conference Call

CymaBay Therapeutics Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cymabay.com

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease.